WEBULL
WebtradeDownload

Indivior Pharmaceuticals (INDV) Declares A Special Dividend, Is The Stock Still Cheap?

Simply Wall St · 1d ago

Special dividend linked to Supernus merger

Indivior Pharmaceuticals (INDV) has declared a one time cash dividend of $8.13 per share, tied directly to the completion of its planned merger with Supernus Pharmaceuticals in early November 2026.

Against that backdrop, Indivior Pharmaceuticals’ share price has eased 0.8% over the past day after a recent 7 day gain of 4.5%, while the 90 day share price return is down 13% even as the 1 year total shareholder return is 57%.

Scan other special situation plays in healthcare by reviewing our curated list of 38 healthcare AI stocks alongside the Indivior Pharmaceuticals news you are assessing today.

Bulls point to Indivior Pharmaceuticals’ long track record of total returns and the merger-linked cash payout. Bears flag the recent 90 day share price drop and execution risk. Which side do the valuation numbers back?

Most Popular Narrative: 29% Undervalued

Indivior Pharmaceuticals last closed at $35.91, while the most followed narrative anchors fair value around $50.83. As a result, the merger-linked special dividend now sits within a framework that already treats the stock as materially discounted on fundamentals.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

Portfolio and geographic focus on core markets such as the U.S., Canada and Australia, alongside streamlined R&D and optimized Rest of World operations, is intended to reduce complexity and volatility, which may improve earnings visibility and support more predictable free cash generation.

See why 6 investors see Indivior Pharmaceuticals as 29% undervalued.

Result: Fair Value of $50.83 (UNDERVALUED)

Still, this upbeat Indivior Pharmaceuticals story could be challenged if SUBLOCADE uptake slows, or if cost savings under the Indivior Action Agenda prove harder to capture.

Find out about the key risks to this Indivior Pharmaceuticals narrative.

Next Steps

Mixed signals around Indivior Pharmaceuticals can make the story feel urgent, which is exactly when it pays to slow down and check the underlying data yourself. To see both sides clearly, review the 5 key rewards and 4 important warning signs.

Looking for more Indivior Pharmaceuticals style ideas?

If you stop with Indivior Pharmaceuticals, you risk missing other opportunities that fit your goals, so put the Simply Wall Street Screener to work for you today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.